A Global Compliance Networking System That Leaves No Patient Behind® !
Over a decade ago, the founders of HealthCarePoint, along with several healthcare professionals and some of their family members found themselves facing difficult diagnoses including cancer, paralysis, psychiatric diseases and other disorders. While sharing their personal experience during the process, as both patients and subjects, the founders became disappointed as they struggled with the inefficiencies, redundancies and bureaucratic limitations they encountered within the clinical research system enterprise. This presented a problem they resolved to change. While battling their personal diseases, they found a common purpose: To do everything possible to improve the healthcare and clinical research system by increasing transparency, and becoming more accountable to patients, subjects and the public in general.
How We Give Back
The Research Literacy Connections for Tomorrow’s Cures campaign is a collaboration between the Center for Information and Study on Clinical Research Participation (CISCRP) and BlueCloud® by HealthCarePoint, for which BlueCloud® will donate one dollar per connection made on its online networking platform for CISCRP, in support of education and outreach to students and their families about clinical research. Dollars raised from the campaign will directly support the development of CISCRP’s Medical Heroes: A Traveling Museum Exhibit, which will engage elementary through high school age children and their families in 12 U.S. cities with interactive and experimental learning about the clinical research process and the role that clinical trials play in advancing public health. To learn more about CISCRP or the Medical Heroes Travel Museum, please visit www.ciscrp.org. Your BlueCloud® connections will make a difference for tomorrow’s cures!
“When NINDS produced a full and accurate, high quality program for the NIH Stroke Scale in 2002, we knew it was something the research community badly needed. But I don’t think we could have ever dreamed that the program would reach this many people. We are impressed by the fact that this important medical tool has been made available globally, and to so many disciplines.”Walter J. Koroshetz, MDNIH